Skip to main content
SLGL
NASDAQ Life Sciences

Sol-Gel Q1 Revenue Misses Expectations by 90%, Reports $100K Sales and $3.7M Loss

Reported by Reuters
Sentiment info
Negative
Importance info
7
Price
$71.4
Mkt Cap
$241.252M
52W Low
$6.8
52W High
$97.97
Market data snapshot near publication time

Summary

Sol-Gel Technologies reported Q1 revenue of $100,000 and a net loss of $3.7 million. This revenue figure is a significant miss compared to the $900,000 Reuters had previously expected. While the short-term commercial performance is weaker than anticipated, this earnings report coincides with a highly positive 6-K filing announcing a patent extension for SGT-610 until 2044 and funding secured into 2028, which provides strong long-term positive context.

At the time of this announcement, SLGL was trading at $71.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $241.3M. The 52-week trading range was $6.80 to $97.97. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.


Price Chart

Share this article

Copied!

SLGL - Latest Insights

SLGL
May 28, 2026, 8:01 AM EDT
Source: Reuters
Importance Score:
7
SLGL
May 28, 2026, 8:00 AM EDT
Filing Type: 6-K
Importance Score:
8
SLGL
May 19, 2026, 8:32 AM EDT
Source: Reuters
Importance Score:
7
SLGL
Apr 15, 2026, 12:37 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
SLGL
Mar 24, 2026, 5:14 PM EDT
Filing Type: 424B5
Importance Score:
8
SLGL
Mar 24, 2026, 4:05 PM EDT
Filing Type: 4
Importance Score:
8
SLGL
Mar 23, 2026, 9:39 PM EDT
Source: Reuters
Importance Score:
9
SLGL
Mar 19, 2026, 8:51 AM EDT
Filing Type: 20-F
Importance Score:
8